EUVIMEDEUVIMED entdecken
Crossref

Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity

SANTI ARANA BALLESTER, CRUZ BARTOLOMÉ MORENO

Boletín de Información Farmacoterapéutica de Navarra · 2023

DOI: 10.54095/bitn20233104en ↗

Kurz gefasst

Fachartikel in der Zeitschrift Boletín de Información Farmacoterapéutica de Navarra, 2023. Verfasst von SANTI ARANA BALLESTER und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The prevalence of obesity has tripled over the past 40 years. Several glucagon-like peptide 1 receptor agonists (GLP1a) have been authorised for weight loss recently. OBJECTIVE To analyse the evidence supporting the use of GLP1a for overweight and obesity in non-diabetic adult patients. To discuss the role thereof in the fight against the obesity epidemic. Methods. The pivotal clinical trials of liraglutide, semaglutide and tirzepatide in non-diabetic adult patients published up until April 2024 were examined. Trials studying the effects of suspending treatment and one trial in patients with established cardiovascular disease were also analysed. RESULTS GLP1a provoke weight loss while treatment remains ongoing. In secondary prevention, semaglutide reduces the risk of cardiovascular events to a modest extent. The use of surrogate outcomes, the proportion of withdrawals and problems of external validity limit the relevance of these findings. Gastrointestinal adverse events are common and the incidence of serious events is notable. CONCLUSIONS The role of GLP1a in therapeutic medicine remains to be clearly defined, therefore the prescription thereof should be restricted to the sub-groups that will achieve the greatest benefit. Accessibility to lifestyle interventions should be ensured. The solution to the obesity epidemic requires political intervention regarding the social factors that promote it.

Zitieren

APA

BALLESTER, S. A., & MORENO, C. B. (2023). Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity. Boletín de Información Farmacoterapéutica de Navarra. https://doi.org/10.54095/bitn20233104en

Vancouver

BALLESTER SA, MORENO CB. Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity. Boletín de Información Farmacoterapéutica de Navarra. 2023. doi:10.54095/bitn20233104en

BibTeX
@article{BALLESTER2023,
  author = {BALLESTER, SANTI ARANA and MORENO, CRUZ BARTOLOMÉ},
  title = {Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity},
  journal = {Boletín de Información Farmacoterapéutica de Navarra},
  year = {2023},
  doi = {10.54095/bitn20233104en}
}
Kostenlos starten →